Most Read Articles
Dr. Joseph Delano Fule Robles, 5 days ago

A recent study conducted by The University of Hong Kong (HKU) revealed that long-term use of proton pump inhibitors (PPIs) is associated with a significantly increased risk of gastric cancer even in patients who have had Helicobacter pylori eradicated. 

5 days ago
The 5-year survival rates for human papillomavirus (HPV)-associated cancers vary greatly according to age and race, with Caucasians and younger patients tending to have better survival, according to a recent US study.
6 days ago
High levels of marijuana exposure appear to not be longitudinally associated with prevalent albuminuria and substantial changes in estimated glomerular filtration rate by cystatin C (eGFRcys), a recent US epidemiological study has shown.
4 days ago
Men with breast cancer have tumours that are typically of the human epidermal growth factor receptor 2-negative Luminal B subtype and positive for oestrogen receptor, progesterone receptor and androgen receptor, according to the results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program study.

Biological outdoes conventional synthetic DMARD for psoriatic arthritis

12 Aug 2017
A new therapy is now available to patients who cannot tolerate DMARDs.

The use of biological disease-modifying antirheumatic drugs (bDMARD) is associated with a minimal disease activity (MDA) status and remission in patients with psoriatic arthritis (PsA) as compared to conventional synthetic (cs)DMARD, according to a recent study.

Additionally, it appears that Psoriatic Arthritis Disease Activity Score (PASDAS) ≤1.9 and MDA 7/7 are stringent remission criteria.

Researchers enrolled patients with PsA (n=109) categorized using the CASPAR criteria and with >6 months follow-up treated with first csDMARD and bDMARD. They assessed disease activity using composite indices tailored for PsA, such as the Disease Activity Index for Psoriatic Arthritis (DAPSA), clinical (c)DAPSA, PASDAS, MDA 5/7 and MDA 7/7.

Remission was identified by DAPSA and cDAPSA score ≤4, MDA 7/7, and PASDAS ≤1.9. MDA and low disease activity (LDA) criteria were identified by MDA 5/7, DAPSA score ≤14, cDAPSA score ≤13 and PASDAS <3.2.

Of the patients enrolled, 79 were receiving stable treatment with bDMARD and 30 with csDMARD.

In general, there were 28 patients (25.6 percent) in cDAPSA remission, 23 (21.1 percent) in DAPSA remission, 19 (17.4 percent) in MDA 7/7 and 13 (11.9 percent) in PASDAS ≤1.9. In addition, 54 patients (49.5 percent) were in MDA 5/7, 80 (73.3 percent) in DAPSA LDA, 79 (72.3 percent) in cDAPSA LDA and 38 (34.8 percent) in PASDAS LDA.

Compared with patients treated with csDMARD, those treated with bDMARD had significantly lower median DAPSA, cDAPSA and PASDAS score.

According to researchers, there are several methods available to define remission or LDA in a complex disease such as PsA.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Dr. Joseph Delano Fule Robles, 5 days ago

A recent study conducted by The University of Hong Kong (HKU) revealed that long-term use of proton pump inhibitors (PPIs) is associated with a significantly increased risk of gastric cancer even in patients who have had Helicobacter pylori eradicated. 

5 days ago
The 5-year survival rates for human papillomavirus (HPV)-associated cancers vary greatly according to age and race, with Caucasians and younger patients tending to have better survival, according to a recent US study.
6 days ago
High levels of marijuana exposure appear to not be longitudinally associated with prevalent albuminuria and substantial changes in estimated glomerular filtration rate by cystatin C (eGFRcys), a recent US epidemiological study has shown.
4 days ago
Men with breast cancer have tumours that are typically of the human epidermal growth factor receptor 2-negative Luminal B subtype and positive for oestrogen receptor, progesterone receptor and androgen receptor, according to the results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program study.